0
Articles |

Prognostic Significance of Supraclavicular Lymph Nodes in Small Cell Lung Cancer : A Study From Four Consecutive Clinical Trials, Including 1,370 Patients

Thierry Urban; Claude Chastang; Fabien Vaylet; Marc Mathieu; Pascal Leclerc; Dominique Paillotin; Bernard Lebeau; the "Petites Cellules" Group
Author and Funding Information

Affiliations: From the Service de Pneumologie, Hôpital Saint-Antoine, Paris,  From the Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris,  From Services de Pneumologie, Hôpitaux de Percy-Clamart, Clamart, France,  From Aulnay sous Bois, France,  From Saint Germain en Laye, France,  From Bois-Guillaume, France

Thierry Urban, MD, Service de Pneumologie, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France; e-mail: thierry.urban@sat.ap-hop-paris.fr


Affiliations: From the Service de Pneumologie, Hôpital Saint-Antoine, Paris,  From the Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris,  From Services de Pneumologie, Hôpitaux de Percy-Clamart, Clamart, France,  From Aulnay sous Bois, France,  From Saint Germain en Laye, France,  From Bois-Guillaume, France

1998 by the American College of Chest Physicians


Chest. 1998;114(6):1538-1541. doi:10.1378/chest.114.6.1538
Text Size: A A A
Published online

Abstract

Study objective: To determine the prognostic significance of supraclavicular lymph node (SCLN) involvement in small cell lung cancer.

Materials and methods: Patients (1,370) with small cell lung cancer were included in four consecutive clinical trials and classified as having either limited or extensive forms of disease using the Veterans Administration staging system.

Results: SCLN was present in 17% of patients (n = 234). Median survival was 258 days for patients with SCLN (n = 234) and 297 days for patients without SCLN (n = 1136) (p = 0.002). SCLN involvement was correlated with the presence of distant metastases at baseline (169 vs 65, p = < 0.001). Median survival was 375 days for patients with limited forms without SCLN (n = 529), 332 days for those with limited forms with SCLN (n = 65) (p = 0.12), 244 days for those with extensive forms without SCLN (n = 604), and 228 days for those with extensive forms with SCLN (n = 169) (p = 0.94). The 2-year survival rates were 17%, 12%, 2%, and 4%, respectively. Cox models confirmed that SCLN did not provide any significant additional prognostic information.

Conclusion: SCLN is highly correlated with extensive forms explaining its overall prognostic value. In limited disease, SCLN is only a minor poor prognostic factor, not justifying any amendment to the staging system currently used.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543